ClinicalTrials.gg
DrugBiological

Odronextamab clinical trials

Also written REGN1979, WHO 11035 and Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody REGN1979.

studies test it
13
open now
9
in phase 3
5
first study started
2015

How each study uses odronextamab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the odronextamab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
22 Aug 2024 · Ordspono · EMEA/H/C/006215 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Odronextamab
12
Ordspono
2

Development codes

REGN1979
12
WHO 11035
3

Other names

Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody REGN1979
3

Studies by the year they started

13 studies that test it; most in 2025 (5)

Studies that test odronextamab, by start year
YearStudies
20151
20161
20191
20233
20242
20255

By phase

A phase 1/2 study counts in both.

Phase 1
4
Phase 2
5
Phase 3
5

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 8 · Other 5

Regeneron Pharmaceuticals (8) · City of Hope Medical Center (1) · University of Washington (1) · University of California, Davis (1) · Gottfried von Keudell, MD PhD (1) · University of Birmingham (1)

Often tested with

Tested in the same studies.

Chimeric Antigen Receptor T-cells (3) · Rituximab (2) · Chimeric Antigen Receptor T-Cell Therapy|Chimeric Antigen Receptor T-cell Therapy (2) · Cemiplimab (1) · Vonsetamig (1) · Zanubrutinib (1) · Loncastuximab tesirine (1) · Ifosfamide (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test odronextamab.

Studies

Open first, then newest update. How each study uses odronextamab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 13

Given beside what is tested · 3 — odronextamab is usual care or a partner of the new treatment

Codes

What other systems call odronextamab · ClinicalTrials.gg INT015708

  • UNII (FDA) 8R5CM46UIOODRONEXTAMABOne source FDA
  • NCI Thesaurus C119615OdronextamabOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.